ANGIOSARCOMA

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the targeted drug pazopanib (and another drug, selinexor, for high-risk patients) to standard chemotherapy and radiation can impr…

This study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. The drug is given through a vein and aims to shrink or control tumors. The main goals are to find the safest dose and understand side effects. About 80 p…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy can help shrink or control advanced soft tissue sarcomas that cannot be removed by surgery. About 45 adults aged 18-75 with certain sarcoma types will receive the combination as their fir…

This study tests whether taking regorafenib for up to 12 months after initial treatment can delay or prevent bone sarcoma from coming back. About 168 patients with various bone sarcomas will be randomly assigned to receive the drug or just be monitored. The goal is to see if the …

This study looks at tissue and imaging data from 800 people with high-risk soft tissue sarcoma to find ways to personalize chemotherapy. Participants either have surgery alone or chemo before surgery. The goal is to build a tumor atlas and a tool to predict who benefits from chem…

This study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…

This study follows 250 people with localized angiosarcoma (a rare cancer of blood vessels) to collect information about the tumor and patient characteristics. No new treatment is given; participants receive standard care. The goal is to better understand the disease and improve f…